Depression of the respiratory system is very common in people who use opioids. Moreover, it can be a threat to life without treatment. PneumoWave aims towards preventing deaths and reducing hospital admissions due to respiratory causes using its wearable digital technology. The biosensors gather real-time physiological information, providing digital biomarkers. However, the company has not established the performance characteristics yet.
Collaborated Clinical Trial
PneumoWave will collaborate with King’s College London on a clinical trial. In the trial, the company’s respiratory monitoring platform will collect the breathing data of patients. It will be those patients that are at risk of developing respiratory depression due to opioid side medication.
PneumoWave, a developmental stage-based therapeutics company is based in Scotland and the US. The company is hopeful that the trial will lead to life-saving interventions that will prevent drug-related deaths.
According to WHO, more than 350,000 deaths across the world are related to opioids. Furthermore, more than 30% of the deaths are due to overdose.
This is the first ongoing trial in collaboration with PneumoWave and King’s Institute of Psychiatry, King’s College London. It is a part of the national program of clinical research. While the company develops therapeutic solutions and digital health for multiple respiratory conditions.
Founder and CEO of PneumoWave, Dr Bruce Henderson said,
“The technology behind PneumoWave was specifically developed to reduce deaths from respiratory conditions. The research facilities at King’s College London, and their highly skilled team, make it one of the few places in the world where the data we require can be safely captured.”
Professor Sir John Strang, King’s College London added,
“Working together with my team, I am very excited about this new collaboration and its potential to apply science to make the world a safer place for one of our most vulnerable groups. With drug-related deaths at an all-time high in the UK and globally, we need to develop better ways to reduce this loss of life. It is essential that we drive new scientific studies and develop new technologies that have real potential to save lives.”
